Literature DB >> 16461995

Urticaria and quality of life.

Jean-Jacques Grob1, Caroline Gaudy-Marqueste.   

Abstract

The common perspective of physicians on chronic urticaria (CU) refers to a benign disorder with no pain and no threat to function or life. Heath-related quality-of-life (HRQOL) tools have demonstrated the extent to which physicians underestimate the impact of this disorder. From the patient perspective, CU affects as many dimensions of the HRQOL as some life-threatening diseases or well-recognized disabling chronic skin disorders, such as psoriasis or atopic dermatitis. Pruritus as well as swelling and wheals triggered by unavoidable events, such as pressure or sweating, greatly contribute to HRQOL impairment. Recent trials have suggested that dermatology-specific HRQOL instruments could be more relevant than more objective severity scores when studying and comparing the benefit of various therapeutic strategies in chronic idiopathic urticaria.

Entities:  

Mesh:

Year:  2006        PMID: 16461995     DOI: 10.1385/CRIAI:30:1:047

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  15 in total

1.  Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria.

Authors:  H S Nelson; R Reynolds; J Mason
Journal:  Ann Allergy Asthma Immunol       Date:  2000-05       Impact factor: 6.347

2.  A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL).

Authors:  I Baiardini; M Pasquali; F Braido; F Fumagalli; L Guerra; E Compalati; M Braga; C Lombardi; O Fassio; G W Canonica
Journal:  Allergy       Date:  2005-08       Impact factor: 13.146

3.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

4.  The impact of chronic urticaria on the quality of life.

Authors:  B F O'Donnell; F Lawlor; J Simpson; M Morgan; M W Greaves
Journal:  Br J Dermatol       Date:  1997-02       Impact factor: 9.302

5.  Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

Authors:  A Y Finlay; G K Khan
Journal:  Clin Exp Dermatol       Date:  1994-05       Impact factor: 3.470

6.  A quantitative approach to perceived health status: a validation study.

Authors:  S M Hunt; S P McKenna; J McEwen; E M Backett; J Williams; E Papp
Journal:  J Epidemiol Community Health       Date:  1980-12       Impact factor: 3.710

7.  A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.

Authors:  A F Finn; A P Kaplan; R Fretwell; R Qu; J Long
Journal:  J Allergy Clin Immunol       Date:  1999-11       Impact factor: 10.793

8.  The extent and nature of disability in different urticarial conditions.

Authors:  E Poon; P T Seed; M W Greaves; A Kobza-Black
Journal:  Br J Dermatol       Date:  1999-04       Impact factor: 9.302

9.  Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria.

Authors:  A K Thompson; A F Finn; W F Schoenwetter
Journal:  J Am Acad Dermatol       Date:  2000-07       Impact factor: 11.527

10.  The effects of antihypertensive therapy on the quality of life.

Authors:  S H Croog; S Levine; M A Testa; B Brown; C J Bulpitt; C D Jenkins; G L Klerman; G H Williams
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

View more
  14 in total

1.  Vasculitis: current status and future directions.

Authors:  Pierre Youinou
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

2.  Cutting edge issues in autoimmunity.

Authors:  Yaniv Sherer; Torsten Matthias; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

3.  Statin effects on regulatory and proinflammatory factors in chronic idiopathic urticaria.

Authors:  M H Azor; J C dos Santos; E A Futata; C A de Brito; C W Maruta; E A Rivitti; A J da Silva Duarte; M N Sato
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

4.  Investigation of patient-specific characteristics associated with treatment outcomes for chronic urticaria.

Authors:  Priyal Amin; Linda Levin; Sarah J Holmes; Jillian Picard; Jonathan A Bernstein
Journal:  J Allergy Clin Immunol Pract       Date:  2015-02-11

5.  Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria.

Authors:  Vippan Goyal; Anu Gupta; Onam Gupta; Dhruvendra Lal; Manharan Gill
Journal:  J Clin Diagn Res       Date:  2017-03-01

6.  Non-interventional study comparing treatment satisfaction in patients treated with antihistamines.

Authors:  Christine De Vos; Krassimir Mitchev; Marie-Etienne Pinelli; Marie-Paule Derde; Rossen Boev
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

7.  Progress and challenges in the understanding of chronic urticaria.

Authors:  Marta Ferrer; Allen P Kaplan
Journal:  Allergy Asthma Clin Immunol       Date:  2007-03-15       Impact factor: 3.406

8.  Whither autoimmunity: the lessons of anti-CCP and B cell depletion.

Authors:  Yehuda Shoenfeld; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

9.  Subjective health and impaired quality of life due to allergies in a representative population survey.

Authors:  Thomas Dorner; Karl H Müller; Hannes Schmidl; Wolfgang Freidl; Willibald J Stronegger; Kitty Lawrence; Michael Kunze; Anita Rieder
Journal:  Wien Med Wochenschr       Date:  2007

10.  Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticaria: A Multicenter, Practice-based Study.

Authors:  Harold Kim; Charles Lynde
Journal:  Arch Drug Inf       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.